Rosacea (Papulopustular Subtype)
Investigational adjunct for papulopustular rosacea subtype with persistent inflammatory lesions; small case series.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for rosacea. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for papulopustular rosacea is investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). One small case series (Wollina 2018 n=18) reports Investigator Global Assessment improvement of 1-2 grades at 12 weeks; there are no randomized controlled trials. Evidence-based therapy per AAD and 2017 ROSCO consensus: topical metronidazole, ivermectin, azelaic acid, or oral doxycycline (sub-antimicrobial 40 mg modified-release). Brimonidine for persistent erythema. Pulsed dye laser or IPL for telangiectasias.
- Riesgos principales
- Bleeding from bite sites for 6 to 24 hours after detachment
- Worsening of facial erythema or flushing in the short term
- Post-inflammatory hyperpigmentation, especially in darker Fitzpatrick skin
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Permanent small scars at bite sites on the face
- Trigger of ocular rosacea if leech placed near eyelids
- Delay of evidence-based topical or oral therapy
- Quién no debería considerar esto
- Patients with ocular rosacea (specialty management required)
- Patients with phymatous rosacea (laser ablation or surgical management)
- Patients with rosacea fulminans (oral isotretinoin or systemic steroid)
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients with darker Fitzpatrick skin types at high PIH risk
- Pregnant patients
- Patients who have not been offered topical metronidazole, ivermectin, or oral doxycycline
- Qué preguntar a su clínico
- Have I tried topical metronidazole, ivermectin, or azelaic acid for at least 12 weeks?
- Am I a candidate for sub-antimicrobial doxycycline 40 mg modified-release?
- Should I see an ophthalmologist for ocular rosacea symptoms?
- Will leech placement risk worsening my flushing or burning?
- What is the practitioner's experience with facial leech placement and PIH prevention?
- Are leeches from an FDA-registered supplier and used only once?
- What is the cost and is it covered by insurance? (typically not covered)
- Cuándo buscar atención urgente
- Severe sudden facial swelling with fever (rosacea fulminans — emergency)
- New eye pain, blurred vision, or red painful eye (ocular rosacea)
- Spreading redness, warmth, pus, or red streaks on the face (cellulitis)
- Bleeding from a bite site lasting more than 24 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Qué NO significa esto
- This is NOT FDA-cleared for rosacea.
- A single n=18 case series does NOT establish efficacy versus topical ivermectin, metronidazole, or sub-antimicrobial doxycycline.
- It does NOT mean facial leech application is risk-free — pigment changes and scarring are facial-cosmetic concerns.
- It does NOT substitute for evidence-based topical or oral therapy.
- It does NOT address ocular rosacea or phymatous changes, which require specialty care.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- dermatological
- ICD-10
- L71.0, L71.8, L71.9
- Safety tier
- medium
Evidence Summary
The papulopustular rosacea subtype (per the 2017 ROSCO consensus) is conventionally treated with topical metronidazole, ivermectin, azelaic acid, or oral doxycycline (sub-antimicrobial 40 mg). No controlled clinical trial or published efficacy case series of leech therapy for rosacea has been reported; any use is investigational and mechanistic only. This entry is distinct from the registry's primary rosacea entry, which addresses erythematotelangiectatic disease. Post-inflammatory hyperpigmentation risk requires careful patient selection.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Wollina U (2018), n=18
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Ocular rosacea with active blepharitis or keratitis
- Rhinophyma stage requiring surgical management
- Patients with darker Fitzpatrick types at high PIH risk
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.